Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.76 |
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.76 |
| ▸ | SGK1 | O00141 | 4/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.56 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.55 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768633 | 0.90 | AXL (0.92) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL8320560 | 0.89 | MAP3K11 (0.69) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL8317528 | 0.89 | SGK1 (0.74) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL8320015 | 0.87 | MAPK8 (0.65) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL8320557 | 0.86 | MAPK8 (0.70) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL3774587 | 0.86 | AXL (1.00) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL8442334 | 0.86 | AXL (0.54) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL8320090 | 0.86 | AXL (0.62) | AXLCAMKK2SGK1MAPK8MAPK9 | |
| SCHEMBL14049065 | 0.85 | DYRK1A (0.79) | AXLMAPK8MAPK9MAPK10CLK1 | |
| SCHEMBL8322707 | 0.84 | MAPK8 (0.61) | AXLCAMKK2SGK1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | AXL 3999/4885CAMKK2 94/4885SGK1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.